CAMPFIRE: A Study of Abemaciclib (LY2835219) in Participants With Ewing's Sarcoma

Summary

The purpose of this study is to measure the benefit of adding abemaciclib to chemotherapy (irinotecan and temozolomide) for Ewing's sarcoma that has come back or did not respond to treatment. This trial is part of the CAMPFIRE master protocol, which is a platform to speed development of new treatments for children and young adults with cancer. Your participation in this trial could last 11 months or longer, depending on how you and your tumor respond.

Timeline

Start

2022-09-20

Primary completion

2025-01-15

Completion

2026-12

Outcome

Mixed primary results

registry Posterior Mean Hazard Ratio 0.530 (80% CI 0.317 to 0.783) NCT05440786 ↗

registry p = 0.281; Hazard Ratio (HR) 0.639 (95% CI 0.282 to 1.449) NCT05440786 ↗

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Abemaciclib	Small molecule	55 mg/m2	Oral
Subject	Abemaciclib	Small molecule	100 mg	Oral
Background	Irinotecan	Small molecule	50 mg/m2	Intravenous
Background	Temozolomide	Small molecule	100 mg/m2	Oral

Indications